Induction chemotherapy and molecular MRD influence outcomes in <i>KMT2A</i> -rearranged AML
Abstract
Abstract We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.
Article Details
Authors (21)
Jad Othman
3The University of Sydney, Sydney, Australia
Nicola Potter
5King's College London, London, United Kingdom
Sylvie D. Freeman
47School of Infection, Inflammation and Immunology, University of Birmingham College of Medicine and Health, Birmingham, United Kingdom
Nicholas McCarthy
6Department of Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham College of Medicine and Health, Birmingham, United Kingdom
Jelena Jovanovic
1King's College London, Department of Medical and Molecular Genetics, London, United Kingdom
Manohursingh Runglall
1King's College London, Department of Medical and Molecular Genetics, London, United Kingdom
Joanna Canham
5Cardiff University, Cardiff, United Kingdom
Ian Thomas
Cardiff University, Cardiff, United Kingdom
Sean Johnson
15Cardiff University, Centre for Trials Research, Cardiff, United Kingdom
Amanda Gilkes
42Department of Haematology, University of Cardiff, Cardiff, United Kingdom
Jamie Cavenagh
8Haematology, St Bartholomew’s Hospital, Barts Health NHS Trust, London, United Kingdom
Panagiotis Kottaridis
9Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom
David Taussig
10The Royal Marsden NHS Foundation Trust, London, United Kingdom
Claire Arnold
8Belfast City Hospital, Belfast, United Kingdom
Claire Hemmaway
12Department of Haematology, Auckland Hospital, Auckland, New Zealand
Dominic Culligan
15University of Aberdeen, Aberdeen, United Kingdom
Ulrik Malthe Overgaard
Copenhagen University Hospital, Copenhagen, Denmark
Mike Dennis
The Christie NHS, Manchester, United Kingdom
Alan K. Burnett
15Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, United Kingdom
Nigel H. Russell
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Richard Dillon
5King's College London, London, United Kingdom